CtDNA Clearance With Neoadjuvant Durvalumab Plus Tremelimumab and EV for Cisplatin-Ineligible MIBC

At the ESMO Congress 2024, Alexandra Drakaki, MD, of University of California, Los Angeles, highlights the VOLGA study and its practice-changing potential for patients with muscle-invasive bladder cancer.

She explains how durvalumab, tremelimumab, and enfortumab vedotin work in tandem with each other, how ctDNA clearance and detection correlate with pathologic response and event-free survival in the study, and next steps for further research.